Long-Term Outcomes of Kidney Transplantation in Fabry Disease by Ersözlü, Sara et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Long-Term Outcomes of Kidney Transplantation in Fabry Disease
Ersözlü, Sara; Desnick, Robert J; Huynh-Do, Uyen; Canaan-Kühl, Sima; Barbey, Frédéric; Genitsch,
Vera; Müller, Thomas; Cheetham, Marcus; Flammer, Andreas; Schaub, Stefan; Nowak, Albina
Abstract: BACKGROUND: Fabry disease is a rare X-linked lysosomal storage disorder caused by mu-
tations in the ￿-galactosidase A gene that obliterate or markedly reduce ￿-galactosidase A activity. This
results in the systemic accumulation of its glycosphingolipid substrates in body fluids and organs, includ-
ing the kidney. Fabry nephropathy can lead to end-stage renal disease requiring kidney transplantation.
Little is known about its long-term outcomes and the overall patient survival after kidney transplantation.
METHODS: Here, we report 17 Fabry patients (15 males, 2 females) who received kidney transplants and
their long-term treatment and follow-up at 4 specialized Fabry centers. RESULTS: The posttransplant
follow-up ranged to 25 years, with a median of 11.5 [range 0.8-25.5] years. Graft survival was similar
and death-censored graft survival was superior to matched controls. Fabry patients died with function-
ing kidneys, mostly from cardiac causes. In 2 males 14 and 23 years posttransplant, the grafts had a
few typical FD lamellar inclusions, presumably originating from invading host macrophages and vascular
endothelial cells. CONCLUSIONS: We conclude that kidney transplantation has an excellent long-term
outcome in Fabry disease.
DOI: https://doi.org/10.1097/TP.0000000000002252
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-152422
Journal Article
Accepted Version
Originally published at:
Ersözlü, Sara; Desnick, Robert J; Huynh-Do, Uyen; Canaan-Kühl, Sima; Barbey, Frédéric; Genitsch,
Vera; Müller, Thomas; Cheetham, Marcus; Flammer, Andreas; Schaub, Stefan; Nowak, Albina (2018).
Long-Term Outcomes of Kidney Transplantation in Fabry Disease. Transplantation:Epub ahead of print.
DOI: https://doi.org/10.1097/TP.0000000000002252
D
ow
nloaded
from
https://journals.lw
w
.com
/transplantjournalby
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
3K
irptP
A
LrnD
i+TL0TbiLtN
hR
Y
G
30LM
gO
hE
Y
ax8qR
Jm
s=
on
07/12/2018
Downloadedfromhttps://journals.lww.com/transplantjournalbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3KirptPALrnDi+TL0TbiLtNhRYG30LMgOhEYax8qRJms=on07/12/2018
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
Transplantation Publish Ahead of Print
DOI: 10.1097/TP.0000000000002252
 1 
 
Long-Term Outcomes of Kidney Transplantation in Fabry Disease 
 
Sara Ersözlü, MD
1,2
, Robert J. Desnick, PhD, MD Professor
3
,  
Uyen Huynh-Do, MD Professor
4
, Sima Canaan-Kühl, MD
5
, Frédéric Barbey, MD
6
,  
Vera Genitsch, MD
7
, Thomas Müller, MD Professor
8
, Marcus Cheetham, PhD Professor
2
, 
Andreas Flammer, MD
9
, Stefan Schaub, MD Professor
10
, Albina Nowak, MD
2,9
 
 
1
Department of Cardiology, Inselspital, Bern University Hospital, Bern, Switzerland 
2
Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland  
3
Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, 
New York, New York, United States 
4
Department of Nephrology and Hypertension, Inselspital, University of Bern, Bern, 
Switzerland 
5
Division of Nephrology and Intensive Care Medicine, University Hospital Charité, Berlin, 
Germany 
6
Center of Molecular Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland 
7
Institute of Pathology, University Bern, Bern, Switzerland 
8
Department of Nephrology, University Hospital Zurich, Zurich, Switzerland  
9
University Heart Centre, University Hospital Zurich, Zurich, Switzerland  
10
Clinic for Transplantationimmunology and Nephrology, University Hospital Basel, Basel, 
Switzerland 
 
 
 
 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 2 
Corresponding author: 
PD Dr. Albina Nowak 
Universitäres Herzzentrum Zürich 
Universitätsspital Zürich 
Rämistrasse 100 
CH-8091 Zürich 
E-Mail:  albina.nowak@usz.ch 
 
Authorship 
SE and AN participated in the research design, performance of the research, data analysis and 
writing of the paper. UHD, SCK, FB and SS participated in the performance of the research, 
data analysis and writing of the paper. RJD and VG participated in data analysis and the 
writing of the paper. TN, AF and MC participated in writing of the paper.  
 
Disclosures 
SE received a travel grant from Sanofi-Genzyme and Shire. AN received lecturing honoraria, 
and research support from Sanofi Genzyme and Shire. RJD is a consultant to Alexion 
Pharmaceuticals, Amicus Therapeutics, Sanofi-Genzyme, and Sangamo Therapeutics, has 
founder shares of Amicus Therapeutics and options of Sangamo Therapeutics, and receives 
royalties from Sanofi-Genzyme and Shire HRT. FB received a research grant from Shire. The 
other authors have no conflicts of interests. 
 
Funding 
AN received financial publication support for this paper from Sanofi Genzyme. 
 
 
 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 3 
Abbreviations 
α-Gal A, α-galactosidase A 
α-Gal B, α-N-acetylgalactosaminidase  
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration 
DSA, Donor Specific Antigens 
eGFR, estimated glomerular filtration rate  
EM, electron microscopy 
ERT, enzyme replacement therapy  
ESRD, end stage renal disease  
FD, Fabry disease  
Gb3, globotriasylceramide 
GBM, glomerular basal membrane 
GLA, α-galactosidase A gene 
HLA, human leucocyte antigen 
KTx, kidney transplantation  
LM, light microscopy 
Lyso-Gb3, globotriaosylsphingosine
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 4 
Abstract  
Background: Fabry disease is a rare X-linked lysosomal storage disorder caused by mutations 
in the α-galactosidase A gene that obliterate or markedly reduce α-galactosidase A activity. 
This results in the systemic accumulation of its glycosphingolipid substrates in body fluids 
and organs, including the kidney. Fabry nephropathy can lead to end-stage renal disease 
requiring kidney transplantation. Little is known about its long-term outcomes and the overall 
patient survival after kidney transplantation.  
Methods: Here, we report 17 Fabry patients (15 males, 2 females) who received kidney 
transplants and their long-term treatment and follow-up at 4 specialized Fabry centers.  
Results: The posttransplant follow-up ranged to 25 years, with a median of 11.5 [range 0.8-
25.5] years. Graft survival was similar and death-censored graft survival was superior to 
matched controls. Fabry patients died with functioning kidneys, mostly from cardiac causes. 
In 2 males 14 and 23 years posttransplant, the grafts had a few typical FD lamellar inclusions, 
presumably originating from invading host macrophages and vascular endothelial cells. 
Conclusions: We conclude that kidney transplantation has an excellent long-term outcome in 
Fabry disease.  
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Introduction 
Fabry’s disease (FD), a rare X-linked lysosomal storage disorder, is caused by mutations in the 
α-galactosidase A gene (GLA)1. The mutations result in markedly decreased or absent α-
galactosidase A (α-Gal A) enzymatic activity and the accumulation of its major substrate, 
globotriaosylceramide (Gb3), and its deacylated derivative, globotriaosylsphingosine (Lyso-
Gb3)
2
 in the fluids and cellular lysosomes throughout the body. Progressive Gb3 accumulation 
causes major organ damage, most frequently of the kidneys and heart
1
.  
There are 2 major subtypes: the “Classic” and “Later-Onset” phenotypes. Classic males have 
little or no residual α-Gal A activity, have prominent vascular endothelial cell 
glycosphingolipid accumulation and have childhood or adolescence onset of severe 
acroparesthesias, angiokeratoma, hypohidrosis, corneal and lenticular opacities, and with age 
progress to early demise primarily due to cardiac and renal involvement
3,4
. Males with the 
Later-Onset phenotype have residual -Gal A activity, no vascular endothelial cell 
glycosphingolipid accumulation, lack the childhood/ adolescent hallmark symptoms, and 
predominantly suffer from progressive nephropathy, cardiomyopathy and cerebrovascular 
disease in adulthood
5-7
. Heterozygous females also can be affected by the disease, however, 
their FD manifestations are variable and typically milder due to random X-chromosomal 
inactivation
8,9
.  
This means that Fabry nephropathy can lead to end-stage renal disease (ESRD) requiring 
dialysis or transplantation (KTx) in males, and severely affected heterozygotes with both 
phenotypes 
4,10,11
. The first kidney transplant in a FD patient was conducted in 1967 in Basel, 
Switzerland
12
. Initial reports advised against KTx in FD because of infectious and other 
complications and early transplant demise
13
. Limited information is available about the long-
term outcome of KTx in FD, particularly post-transplant survival
14-16
. Later studies showed 
good survival rates, but mortality rates were high compared with non-Fabry recipients, mainly 
due to cardiovascular events
16
. The longest previously reported graft survival was 10 years
14-18
, 
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and most patient outcome studies were conducted before the introduction of enzyme 
replacement therapy (ERT),
14-17
 or did not include data on the duration of and the number of 
patients undergoing ERT
15,16
. Moreover, previous studies, most of which were registry analyses, 
did not report GLA mutations of recipients to confirm the FD diagnosis and determine the 
phenotypic subtype, nor were systematic transplant biopsies performed
14-18
. The impact of 
posttransplantation ERT was also unclear. Because the normal endogenous α-Gal A activity in 
the graft should be sufficient for graft health, the recently reported European Best Practice 
Guideline on Fabry nephropathy recommended that ERT should be continued for nonrenal 
indications
19
. Some early reports, particularly before the advent of ERT, found Gb3 deposits in 
kidney transplants, albeit in host macrophages or vascular endothelial cells that infiltrated the 
allograft
20-23
. To further document the effects of renal transplants in FD, we conducted a long-
term observational study that included follow-up of KTx grafts for up to 25 years in 17 Fabry 
patients, who were regularly treated and followed at 4 specialized FD centers. 
 
Materials and Methods 
We investigated the FD patients that were transplanted and followed in Zurich, Bern and 
Lausanne, Switzerland and in Berlin, Germany. This study was conducted in accordance with 
the Declarations of Helsinki and Istanbul and approved by the respective center’s ethics 
committee (KEK-ZH-Nr. 2014-0534, PB_2016-00360 and EKNZ 2015-403). All living 
patients provided written informed consent.  
 
Patient selection, characteristics and follow-up  
The databases of all participating centers were screened for patients with FD and kidney 
transplantation and all identified patients were included in the study. The patients (15 males 
and 2 females) were all regularly treated between 1979 and March 2017 at the 4 specialized FD 
centers in Zurich (patients 1-9), Bern (patients 10-12), Lausanne (patient 17) and Berlin 
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(patients 13-16). The clinical data were extracted from medical records. Phenotyping was 
determined as reported previously
24
. Separate annual follow-ups were carried out in the Fabry 
and transplant centers. ERT was initiated according to the written local guidelines. Accordingly, 
ERT was indicated in all males, independent from age, phenotype and symptoms. In 
heterozygotes, ERT was indicated if they had proteinuria of more than 300 mg per day, Fabry-
typical kidney biopsy findings, signs of Fabry cardiomyopathy such as left ventricular 
hypertrophy or arrhythmia, stroke or transient ischemic attack (TIA), persistent FD-related 
neuropathic pains despite conventional analgetic therapy, and or gastrointestinal symptoms. 
ERT was prescribed at the licensed dose of either 0.2 mg/kg body weight of recombinant 
agalsidase-alpha (Replagal) or 1 mg/kg body weight agalsidase-beta (Fabrazyme) and given 
intravenously every 14 days. 
Endpoint evaluation 
Cumulative patient and graft survival and death-censored graft survival were determined. 
Transplant function was regularly monitored at the respective FD and transplant centers. If a 
patient died outside the Fabry center, the date of death was obtained from the patient’s general 
practitioner, family, or home care nurse administering ERT. All events were prospectively 
recorded and coded. The follow-up time was based on the date of the patient’s death, graft loss, 
or the end of the study (March 31, 2017). Graft survival analysis was used to estimate the 
probability of a functioning graft at the study end. Graft failure was defined as graft loss or 
patient death, whichever came first. In addition, death-censored graft survival was used to 
estimate the probability of graft loss irrespective of death. For this purpose, the date of death in 
patients who died with a functioning graft was defined as the last follow-up
25
. 
 
Control group and matching algorithm  
Data from non-FD KTx recipients were from the kidney transplant registry of the University 
Hospital Basel Switzerland and served as the control group
26
. This registry contains detailed 
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information on over 2220 kidney transplant patients, grouped according to immunosuppression 
era, as previously published by Wehmeier et al, 2016 and classified as: 1
st
 period 1967-1980, 
2
nd
 period 1981-1997, 3
rd
 period 1998-2004 and 4
th
 period 2005-2015
26
. 
To compare graft survival and overall patient survival between FD and matched non-FD KTx 
controls, each FD recipient was best matched and blinded to the outcome in a 1:1 ratio. The 
matching algorithm is shown in Table 1. The FD and non-FD KTx recipients were matched for 
sex, number of transplants, similar age with a maximum of -2/+4 years, and KTx year ± 3 years, 
similar number of human leucocyte antigen (HLA) mismatches ± 2, same status of Donor 
Specific Antigens (DSA), belonged to the same immunosuppression period (when possible), 
and similar immunosuppression regime with a maximum of 1 drug difference (Table 2). A 1:1 
matching ratio was preferred over 1:2 or 1:3 as it would have required further expansion of the 
matching criteria to find several matches for one patient.  
 
KTx outcome and Gb3 depositions  
The latest value of serum creatinine (μmol/l), estimated glomerular filtration rate (eGFR) 
calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation
27
, urinary protein/creatinine (mg/mmol), and albumin/creatinine (mg/mmol) ratios 
were used to assess KTx function. An eGFR below 15 ml/min/1.73m
2
 was considered a 
transplant failure. Recurrence of Gb3 deposits in kidney transplants was assessed by electron 
microscopy (EM) and/or histological analysis of kidney tissue from biopsies or autopsies.  
 
Statistical analysis 
Continuous variables were expressed as medians with interquartile ranges. Kaplan-Meier 
analysis and log-rank test of survival distributions were calculated. The statistical analyses 
were performed using the SPSS/PC software package (version 23.0; SPSS Inc., Chicago, IL, 
USA). All statistical tests were two-sided, and P values <0.05 were considered significant.  
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Results  
Patients 
The patients’ demographics, renal data, and KTx-related information are presented in Table 2, 
and detailed clinical information, GLA genotypes, phenotypes, age at death and cause are 
presented in Tables 3a and 3b. There were 14 affected Classic males and 1 male with the Later-
Onset phenotype who were diagnosed with FD at median ages of 34 [21-43] and 49 years, 
respectively. In addition, there were 2 severely affected heterozygotes, both from Classically 
affected families, who were diagnosed at ages 38 and 54 years. The 15 male and 2 female 
patients were treated and followed for up to 25 years, with a median patient age of 53 [45-60] 
years as of March 31, 2017 or at death. In the majority, nephropathy was first diagnosed at 
ESRD, which then led to the diagnosis of FD. Diagnosis of nephropathy in the Classically 
affected males was made at the median age of 31 [21-43] years, in the Later-Onset male at 49 
years, and at 25 and 42 years in the 2 heterozygotes. Chronic dialysis was initiated at a median 
age of 33 [22-43] years in the Classically affected males and at 38 years in 1 heterozygote, and 
continued for a median time of 1 [0.25-3.7] years before KTx was undertaken at the median age 
of 44 [28-47] years. 11 patients received 12 kidneys from deceased and 6 patients from living 
donors. The living donors were 2 normal fathers (both to male recipients), 1 mother (who was 
diagnosed with Fabry disease after donating the kidney to her undiagnosed son), 1 stepmother, 
and 2 spouses. Immunosuppression was prescribed according to local transplantation guidelines 
of the respective period
26
. In this cohort, 5 patients were siblings belonging to 2 families with 
the Classic phenotype. Recipients in Family 1 included Males 7 and 12 and Family 2 included 
Males 8, 9, and 10.  
 
Enzyme replacement therapy  
Fourteen of the transplanted FD patients had ERT: 9 patients started before and continued after 
KTx (4 agalsidase-α, 5 agalsidase-β) and 6 started after KTx (5 agalsidase-α, 1 agalsidase-β). 
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Patient 5, who received 2 transplants was counted in both categories. Their individual estimated 
cumulative agalsidase doses after KTx are indicated in Table 3a. Patient 9 died in the pre-ERT 
era. Patient 10 died shortly after ERT became available. ERT was not provided to Patient 3 due 
to the patient’s frailty and dementia.  
 
Patient and graft survival 
During the median overall follow-up time of 11.5 years [range 0.8-25.5], 11.6 years [7.6-17.1] 
for Classic males, 9.4 years for the Later-Onset male and 0.8 and 1.3 years for the 2 
heterozygotes. Seven Classic males died with functioning renal grafts (Table 3a). The median 
age at death was 59 [47-61] years. Four of the 7 male deaths resulted from cardiac arrest 
secondary to hypertrophic cardiomyopathy and ventricular arrhythmias (in 2 cases, most likely 
triggered septic endocarditis or hepatitis B), 1 died from a brain stem compression due to a 
large basilar artery aneurysm, 1 committed suicide, and 1 cause remains unknown (presumably 
cardiac due to known arrhythmias). The cumulative FD patient survival with KTx is shown in 
Figure 1. Cumulative graft survival in FD patients was similar to that of matched controls 
(Figure 2). Two kidney transplants were lost due to chronic transplant failure, (patients 5 and 7 
after 9 and 22 years respectively). Patient 5 was retransplanted at 9.1 years and patient 7 was on 
the transplant waiting list at the end of this study. However, cumulative death-censored graft 
survival in FD patients was better than that of matched controls (p=0.03; Figure 3). As noted 
above, FD patients mainly died from cardiac events, but with functioning grafts. Overall patient 
and graft survival is shown in Table 4. There were 10 patients who had functioning grafts 10 
years post-KTx that were all Classic males. Of the 10 patients who had functioning transplants 
at 10 years post-KTx, the median survival was 14.6 [11.1-20.2] years.  
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Kidney transplant biopsies 
Twenty KTx biopsies were performed in 11 patients (Table 5). There were 4 patients with graft 
biopsies after at least 10 years (patients 7-10; biopsy after 11.6 - 22.6 years). There was no 
evidence of glycosphingolipid deposits in the transplanted kidneys with 2 exceptions among 
these patients (patients 8 and 9). A few electron-dense lamellar inclusions were identified in 
vascular endothelial cells in a Classic male 14 years posttransplant (Figure 4, patient 9)
28
. The 
invasion of vascular endothelial host cells into the graft endothelium can occur
23
. This recipient 
was not on ERT as he died before it was available. The deceased donor of this recipient was a 
35-year old unrelated male. The other transplant recipient with ultrastructural deposits 
appearing as “zebra bodies” was the younger brother of the above patient (patient 8). He was 
transplanted 14 years before ERT was available; subsequently he received ERT for 9 years, 
after which EM showed a few myelin figures, most likely originating from host histiocytes 
(Figure 5). In contrast, patients 7 (no ERT for 10 years, biopsy after 21.8 years) and patient 10 
(no ERT at all, biopsy after 11.6 years) had no Gb3 deposits. Also in the other biopsies, no FD-
specific changes were found on light and/or EM.  
 
Discussion 
In this study, we found similar overall and superior death-censored graft survival in the FD 
patients compared with non-FD matched controls. To our knowledge, these data describe the 
longest reported experience with KTx in FD - up to 25 years. All of the KTx recipients in our 
cohort who died were Classic males (median age at death: 59 years), who had functioning 
grafts, their deaths mainly due to cardiac events. These findings, therefore, highlight the 
importance of cardiovascular protection and ERT in this population. ERT should be beneficial 
in the long-term outcome of KTx patients, by treating the heart and clearing other host cells 
that can migrate into the graft including macrophages, histiocytes and vascular endothelial 
cells
29
. The recipients’ survival rates were similar to non-FD recipients. Importantly, our high-
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risk population of predominantly Classic males, with most on ERT, survived longer (median 
age at death 59 years) than reported for a FD male population without ERT (mean age at death 
49.9 years)
3
.  
Several case reports of KTx in FD (Table 6) and a few registry studies
14,16,18
 have been 
published in the last 40 years, but all had shorter follow-up periods. Similar to our findings, 
previous studies
14-16
 show patient and graft survival comparable to non-FD patients and found 
cardiac and cardiovascular events as major causes of mortality in FD patients. However, patient 
and graft survival rates in our patients were superior to the rates reported in studies from the 
pre-ERT era: the 10-year patient and graft survival in the present study exceeds 90%, previous 
studies report 67-76% patient and 56-67% graft survival
14,15
.  
KTx remains an important therapeutic option for Fabry nephropathy because ERT, when 
initiated late in the disease course, only slows progression
24,30,31
. Germain et al reported that 
patients who initiated treatment at older ages or had advanced renal disease or both, 
experienced faster disease progression
32
. The mean slope for eGFR for the 20 older patients 
(median age 38 years) with urinary protein/creatinine of >0.5 g/g or ≥50% sclerotic glomeruli 
was −6.82 mL/min/1.73m2/year32. In contrast, the mean slope for eGFR for the 32 younger 
patients (median age 25 years) with urinary protein/creatinine ratio of <0.5 g/g or ≤50% 
sclerotic glomeruli was −1.89 mL/min/1.73 m2/year. In addition, the 3- to 5-year survival rate 
of FD patients on chronic dialysis was less than that of the general dialysis population
33,34
. 
Unfortunately, there are no comparative age-matched Fabry data for our sample from 
Switzerland and Germany that could serve as the denominator. The survival data of our 
transplanted Fabry patients can be compared with those of Fabry patients who underwent renal 
dialysis about 20-25 years ago. Thadhani at al.
34
 (2002) analyzed 137 Fabry disease patients in 
2 cohorts, 1985-93 (93 patients) and 1995-98 (42 patients). Although not age matched, the 
overall 3-year survival for the 1985-93 and 1995-98 groups were 63% and 53%, respectively. 
Tsakiris et al
33
 (1996) reported that the 5-year survival of 83 Fabry dialysis patients reported to 
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the European Registry, who initiated dialysis from 1985-1993, was only 41%. Our findings that 
transplantation offers longer survival rates would support the recommendation that all 
transplantable patients with suitable donors (living-related or histocompatable) should be 
transplanted when possible. 
In our cohort, only 2 grafts in Classic male brothers had renal lysosomal substrate inclusions on 
EM. Lamellar lysosomal inclusions were present in vascular endothelial cells of the older 
brother13.8 years post-KTx (pre-ERT era), presumably due to the endothelial cell invasion 
from the host into the graft
23
. In his younger transplanted brother who began ERT 14.3 years 
posttransplant and was biopsied 22.7 years after KTx, biopsy showed isolated inclusions in 
histiocytes, which also migrated into the transplant from the host. In contrast to these patients, 2 
other patients, who were also not under ERT for a long time (10 and 11.6 years) and were 
biopsied after 11.6 and 21.8 years had no lysosomal inclusions by light and electron 
microscopy. 
An important differential diagnosis in the interpretation of the myelin figures and zebra bodies 
found in renal biopsies are drug-induced phenocopies of FD
1
 - ultrastructural changes that 
appear morphologically similar to those due to FD
35-38
. Certain cationic amphiphilic drugs and 
their derivates are inhibitors of α-Gal A and can cause renal inclusions which appear similar to 
FD inclusions and are reversible after discontinuation
35
: (hydro)-chloroquine
38-40
 and 
amiodarone
41,42
 are direct inhibitors of α-Gal A, and gentamicin35, ranolazine43, pentamidine44 
and macrolids
45
 also cause the phenotype. Silicosis results in inclusions that mimic those in FD, 
and thus, similar observations were made in silica-induced nephropathy
1,46
.   
Early studies reported increased levels of plasma α-Gal A activity post-KTx20,47 which were 
later shown to be due to increased α-N-acetylgalactosaminidase (α-Gal B) activity, an enzyme 
evolutionarily related to α-Gal A48,49, that is assayed using the same fluorogenic substrate. Thus, 
the increased α-Gal A activity was an artefact. Subsequently, one of the authors (RJD) showed 
that plasma α-Gal B activity was increased due to the immunosuppression medications 
(Desnick, RJ unpublished results). 
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Importantly, FD does not recur in kidney transplants, in contrast to other renal diseases
50
. 
Among hereditary systemic diseases, primary hyperoxaluria type 1 or adenine phosphoribosyl 
transferase deficiency have high recurrence rates of renal disease in the transplant
50,51
. In 
cystinosis, cysteine-laden cells were occasionally observed in the grafts, but were found to be 
without clinical relevance
50
. In Alport syndrome, antiglomerular basement membrane 
antibodies were occasionally found
50
. Primary renal diseases that recur in the transplant include 
membranoproliferative glomerulonephritis (ca. 30% in type 1, 80% in type 2
50
), focal 
segmental glomerulosclerosis (30-50%
52
) and IgA nephropathy (50%
50
). This is not the 
experience in FD: if the graft is healthy, it can function well for at least 25 years as documented 
here.  
Specific challenges of KTx in FD should be noted. Recipients or donors might have 
undiagnosed FD because FD is not part of the routine pretransplant work-ups
53
. Individuals 
with unrecognized FD may donate their kidneys to non-Fabry patients (eg
53
), which can lead to 
early graft dysfunction and chronic kidney disease in the living donor and recipient
54
. Living 
kidney donations can occur within families with unrecognized FD relatives
54,55
. Thus, it is 
important to perform genetic testing for FD where there is clinical suspicion of FD or an 
unclear nephropathy.  
A limitation of this report is the size of the patient sample. This is an inherent limitation in rare 
diseases. Moreover, we might be analyzing survivor advantage, as Fabry patients may not reach 
transplantation, especially in the era of late diagnosis. Furthermore, we have no way to 
determine, if all Fabry patients were diagnosed pretransplant. There could have been 
unrecognized Fabry patients with kidney transplantation in whom the diagnosis of FD was not 
made. However, and in contrast to previous KTx reports
14,16,18
, most patients had a graft biopsy, 
and the majority had biopsy or autopsy EM to exclude Gb3 deposits in the graft. EM was not 
conducted in some of the donor kidneys because the deposits were generally considered 
unlikely in a non-FD kidney. On the other hand, light microscopy can identify FD-related 
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kidney changes
11
. The strengths of the study are that it was a multicenter design, had no drop-
outs to follow-up, applied regular multidisciplinary patient assessments, and included the 
complete collection of clinical, biochemical, genetic and phenotypic information; data on the 
immunogenic pretransplantation risk; and regular and serial KTx biopsies. These advantages 
were frequently lacking in other studies. Importantly, this study used a well-matched non-FD 
control group that was also exposed to the same environmental conditions due to medical 
treatment as well as geographic and cultural proximities of the FD and non-FD recipients. As 
Fabry patients requiring transplantation are generally younger than the overall transplant 
patient population, and on that basis might be expected to have better outcomes, we have used 
an age-matched control group to avoid this potential bias. Because it is not sufficient to match 
age and gender to reach an equal start line, we also matched according to the 
immunosuppression era, number of transplants, and presence of DSA as well as HLA 
mismatches. 
Conclusions 
The study shows similar graft survival and superior death-censored graft survival in FD 
patients compared with non-FD matched controls. ERT may improve patient survival and 
protect kidney grafts from invasion of host cells containing Gb3 deposits. Finally, the study 
data further support KTx in FD only using a screened-negative donor for FD. 
 
 
Acknowledgments  
Figure 5 was originally published in Gantenbein et al 1995 (Recurrence of Fabry's disease in a 
renal allograft 14 years after transplantation, Nephrol Dial Transplant, 1995 Volume 10 pages 
287-289) by permission of Oxford University Press.  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 16 
References 
1. Desnick R, Ioannou Y, Eng C. α-galactosidase A deficiency: Fabry disease. In Scriver 
CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of 
Inherited Disease. McGraw-Hill, New York; 2001:3733-3774. 
2. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark 
of Fabry disease. Proc Natl Acad Sci U S A. 2008;105(8):2812-2817. 
3. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of 
nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme 
replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102-2111. 
4. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized 
multisystemic disorder: expert recommendations for diagnosis, management, and 
enzyme replacement therapy. Ann Intern Med. 2003;138(4):338-346. 
5. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease 
with manifestations confined to the myocardium. N Engl J Med. 1991;324(6):395-399. 
6. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed 
hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 
2003;64(3):801-807. 
7. Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Fabry disease: identification of 50 
novel alpha-galactosidase A mutations causing the classic phenotype and three-
dimensional structural analysis of 29 missense mutations. Hum Genomics. 
2006;2(5):297-309. 
8. Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination of presence 
of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol. 
2008;51(21):2082; author reply 2082-2083. 
9. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female 
patients with Fabry disease. Clin Genet. 2016;89(1):44-54. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 17 
10. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement 
in Fabry disease. J Am Soc Nephrol. 2002;13 Suppl 2:S139-143. 
11. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol. 
2002;13 Suppl 2:S134-138. 
12. Buhler FR, Thiel G, Dubach UC, Enderlin F, Gloor F, Tholen H. Kidney transplantation 
in Fabry's disease. Br Med J. 1973;3(5870):28-29. 
13. Maizel SE, Simmons RL, Kjellstrand C, Fryd DS. Ten-year experience in renal 
transplantation for Fabry's disease. Transplant Proc. 1981;13(1 Pt 1):57-59. 
14. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal 
transplantation in patients with Fabry's disease. Transplantation. 2000;69(11):2337-
2339. 
15. Inderbitzin D, Avital I, Largiader F, Vogt B, Candinas D. Kidney transplantation 
improves survival and is indicated in Fabry's disease. Transplant Proc. 
2005;37(10):4211-4214. 
16. Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S. Kidney transplant outcomes 
in patients with Fabry disease. Transplantation. 2009;87(2):280-285. 
17. Obrador GT, Ojo A, Thadhani R. End-stage renal disease in patients with Fabry disease. 
J Am Soc Nephrol. 2002;13 Suppl 2:S144-146. 
18. Cybulla M, Walter KN, Schwarting A, et al. Kidney transplantation in patients with 
Fabry disease. Transpl Int. 2009;22(4):475-481. 
19. Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for screening and 
guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol 
Dial Transplant. 2013;28(3):505-517. 
20. Clarke JT, Guttmann RD, Wolfe LS, Beaudoin JG, Morehouse DD. Enzyme 
replacement therapy by renal allotransplantation in Fabry's disease. N Engl J Med. 
1972;287(24):1215-1218. 
AC
CE
P
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 18 
21. Faraggiana T, Churg J, Grishman E, et al. Light- and electron-microscopic 
histochemistry of Fabry's disease. Am J Pathol. 1981;103(2):247-262. 
22. Friedlaender MM, Kopolovic J, Rubinger D, et al. Renal biopsy in Fabry's disease eight 
years after successful renal transplantation. Clin Nephrol. 1987;27(4):206-211. 
23. McMahon J, Tubbs R, Gephardt G, Steinmuller D. Pseudo-Reoccurence of Fabry’s 
Disease in renal allograft. Paper presented at: LABORATORY INVESTIGATION 
1986. 
24. Nowak A, Koch G, Huynh-Do U, Siegenthaler M, Marti HP, Pfister M. Disease 
Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on 
Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease. Kidney 
Blood Press Res. 2017;42(1):1-15. 
25. Transplantation EEGoR. European best practice guidelines for renal transplantation. 
Section IV: Long-term management of the transplant recipient. IV.13 Analysis of 
patient and graft survival. Nephrol Dial Transplant. 2002;17 Suppl 4:60-67. 
26. Wehmeier C, Georgalis A, Hirt-Minkowski P, et al. 2222 kidney transplantations at the 
University Hospital Basel: a story of success and new challenges. Swiss Med Wkly. 
2016;146:w14317. 
27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 
filtration rate. Ann Intern Med. 2009;150(9):604-612. 
28. Gantenbein H, Bruder E, Burger HR, Briner J, Binswanger U. Recurrence of Fabry's 
disease in a renal allograft 14 years after transplantation. Nephrol Dial Transplant. 
1995;10(2):287-289. 
29. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human 
alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med. 
2001;345(1):9-16. 
30. Weidemann F, Niemann M, Stork S, et al. Long-term outcome of enzyme-replacement 
AC
CE
TE
D
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 19 
therapy in advanced Fabry disease: evidence for disease progression towards serious 
complications. J Intern Med. 2013;274(4):331-341. 
31. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry 
disease: a randomized trial. Ann Intern Med. 2007;146(2):77-86. 
32. Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement 
therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 
2015;52(5):353-358. 
33. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in 
Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA 
Registry. Nephrol Dial Transplant. 1996;11 Suppl 7:4-20. 
34. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the 
United States. Kidney Int. 2002;61(1):249-255. 
35. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional 
consequences? Exp Biol Med (Maywood). 2001;226(9):825-830. 
36. Sakuraba H, Tsukimura T, Tanaka T, et al. Clinical and biochemical investigation of 
male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a 
pitfall in diagnosis of Fabry disease. J Nephropathol. 2015;4(3):91-96. 
37. Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic 
phospholipidosis mimicking Fabry disease. Am J Kidney Dis. 2006;48(5):844-850. 
38. de Menezes Neves PDM, Machado JR, Custodio FB, et al. Ultrastructural deposits 
appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports. 
BMC Nephrol. 2017;18(1):157. 
39. Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH. 
Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol. 2005;18(5):733-
738. 
40. Muller-Hocker J, Schmid H, Weiss M, Dendorfer U, Braun GS. Chloroquine-induced 
AC
CE
PT
E
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 20 
phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the 
literature. Hum Pathol. 2003;34(3):285-289. 
41. Pintavorn P, Cook WJ. Progressive renal insufficiency associated with amiodarone-
induced phospholipidosis. Kidney Int. 2008;74(10):1354-1357. 
42. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-induced lipid 
storage disease. Arch Ophthalmol. 1981;99(2):257-261. 
43. Scheurle C, Dammrich M, Becker JU, Baumgartel MW. Renal phospholipidosis 
possibly induced by ranolazine. Clin Kidney J. 2014;7(1):62-64. 
44. Filippone EJ, Carson JM, Beckford RA, et al. Sirolimus-induced pneumonitis 
complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a 
case report. Transplant Proc. 2011;43(7):2792-2797. 
45. Munic V, Banjanac M, Kostrun S, et al. Intensity of macrolide anti-inflammatory 
activity in J774A.1 cells positively correlates with cellular accumulation and 
phospholipidosis. Pharmacol Res. 2011;64(3):298-307. 
46. Banks DE, Milutinovic J, Desnick RJ, Grabowski GA, Lapp NL, Boehlecke BA. 
Silicon nephropathy mimicking Fabry's disease. Am J Nephrol. 1983;3(5):279-284. 
47. Desnick RJ, Allen KY, Simmons RL, et al. Fabry disease: correction of the enzymatic 
deficiency by renal transplantation. Birth Defects Orig Artic Ser. 1973;9(2):88-96. 
48. Wang AM, Desnick RJ. Structural organization and complete sequence of the human 
alpha-N-acetylgalactosaminidase gene: homology with the alpha-galactosidase A gene 
provides evidence for evolution from a common ancestral gene. Genomics. 
1991;10(1):133-142. 
49. Wang AM, Bishop DF, Desnick RJ. Human alpha-N-acetylgalactosaminidase-
molecular cloning, nucleotide sequence, and expression of a full-length cDNA. 
Homology with human alpha-galactosidase A suggests evolution from a common 
ancestral gene. J Biol Chem. 1990;265(35):21859-21866. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 21 
50. Ramos EL, Tisher CC. Recurrent diseases in the kidney transplant. Am J Kidney Dis. 
1994;24(1):142-154. 
51. Bollee G, Cochat P, Daudon M. Recurrence of crystalline nephropathy after kidney 
transplantation in APRT deficiency and primary hyperoxaluria. Can J Kidney Health 
Dis. 2015;2:31. 
52. Rudnicki M. FSGS Recurrence in Adults after Renal Transplantation. Biomed Res Int. 
2016;2016:3295618. 
53. Paull LS, Lipinski MJ, Wilson WG, Lipinski SE. Female with Fabry Disease 
Unknowingly Donates Affected Kidney to Sister: A Call for Pre-transplant Genetic 
Testing. JIMD reports. 2012;4:1-4. 
54. Popli S, Molnar ZV, Leehey DJ, et al. Involvement of renal allograft by Fabry's disease. 
Am J Nephrol. 1987;7(4):316-318. 
55. Odani K, Okumi M, Honda K, Ishida H, Tanabe K. Kidney transplantation from a 
mother with unrecognized Fabry disease to her son with low alpha-galactosidase A 
activity: A 14-year follow-up without enzyme replacement therapy. Nephrology 
(Carlton). 2016;21 Suppl 1:57-59. 
56. Perrier S, Gauquelin L, Tetreault M, et al. Recessive Mutations in NDUFA2 Cause 
Mitochondrial Leukoencephalopathy. Clin Genet. 2017. 
57. Clement M, McGonigle RJ, Monkhouse PM, et al. Renal transplantation in Anderson-
Fabry disease. J R Soc Med. 1982;75(7):557-560. 
58. Bannwart F. Fabry's disease. Light and electron microscopic cardiac findings 12 years 
after successful kidney transplantation. Schweiz Med Wochenschr. 1982;112(48):1742-
1747. 
59. Mosnier JF, Degott C, Bedrossian J, et al. Recurrence of Fabry's disease in a renal 
allograft eleven years after successful renal transplantation. Transplantation. 
1991;51(4):759-762. 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 22 
60. Erten Y, Ozdemir FN, Demirhan B, Karakayali H, Demirag A, Akkoc H. A case of 
Fabry's disease with normal kidney function at 10 years after successful renal 
transplantation. Transplant Proc. 1998;30(3):842-843. 
  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 23 
Figure Legends 
Figure 1: Cumulative survival of FD patients after KTx. 
Cumulative patient survival (Kaplan-Meier estimates) is shown for all FD patients after kidney 
transplantation (n=17). The median age at the end of the study was 53 [45-60] years. Seven 
patients, all Classic males, died at a median age of 59 [47-61] years. 
 
Figure 2: Cumulative graft survival in FD patients and matched controls. 
Cumulative graft survival is shown in FD patients and matched controls. Graft survival analysis 
was censored at graft loss or patient death, whichever came first. Graft survival is shown to be 
similar in FD patients and matched controls.  
 
Figure 3: Death-censored graft survival in FD patients and matched controls. 
Cumulative death-censored graft survival is shown in FD patients and matched controls. Death-
censored graft survival analysis is shown to be superior in Fabry patients, who mainly died with 
functioning kidneys, mostly from cardiac causes. 
 
Figure 4: Electron microscopy of a kidney transplant 14 years without ERT. 
Formalin fixed and refixed in glutaraldehyde. Vascular endothelial cells showing numerous 
lamellar bodies in a patient with the mutation p.V390CfsX9. (EM x 3700, inset x 83 700). 
Previously published in Gantenbein et al, 1995 (Recurrence of Fabry's disease in a renal 
allograft 14 years after transplantation. Nephrol Dial Transplant. 1995;10(2):287-9
28
), with 
permission. 
 
Figure 5:  Electron microscopic findings of a kidney transplant biopsy in a recipient 
with Fabry Disease 14 years without ERT. 
Single inclusions with lamellated structures – myeloid body – in a histiocyte, migrated into the 
graft vascular endothelium (A) (TEM, × 2800) and in a histiocyte, intercalated into a graft 
podocyte (C). B and D: Higher magnification of the myeloid bodies showing the included 
storage material.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Tables  
Table 1. The matching algorithm of FD and non-FD recipients. 
Parameter Deviation 
 
Sex 
↓ 
Year of transplantation 
↓ 
Age at transplantation 
↓ 
Number of transplants 
↓ 
Presence of DSA 
↓ 
HLA mismatches 
↓ 
Immunosuppression era 
↓ 
Immunosuppression drugs 
- 
 
± 3 years 
 
-2/+4 years 
 
- 
 
- 
 
± 2 
 
± 1 
 
max. 1 drug 
 
Abbreviations: DSA = donor specific anti-HLA antibodies; HLA = human leucocyte antigen; max= 
maximum. 
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Table 2. Demographics, donor type, baseline immunogenic risk, and clinical outcomes in FD recipients and matched non-FD controls.  
 
Abbreviations: A = azathioprin; C = cyclosporine; DSA = donor specific anti-HLA antibodies; ESRD = end stage renal disease; FD = Fabry disease; f = female; HLA = 
human leucocyte antigen; KTx = kidney transplant; m = male; M = mycophenolate, P = prednisone; T = tacrolimus; VUR= vesicoureteral reflux. *first and ** second 
transplant in the same FD recipient. 
Cause of ESRD Sex Age at KTx Year of KTx Donor type Number of HLA 
mismatches 
Presence 
of DSA 
Baseline immuno-
suppression 
Graft loss Death 
FD (1) 
Interstitial nephropathy 
m 24 
26 
2005 
2002 
living 
living 
5 
3 
no 
 
M, P, C 
M, P, C 
no 
no 
no 
no 
FD (2) 
Extracapillary glomerulonephritis type II 
m 40 
41 
1995 
1993 
deceased 
living 
3 
3 
no 
 
A, P, C 
A, P, C 
no 
yes 
yes 
no 
FD (3) 
Polycystic kidney disease 
m 
 
45 
45 
1993 
1994 
deceased 
living 
4 
3 
no 
 
A, P, C 
A, P, C 
no 
no 
no 
no 
FD 56 
Hypertensive nephropathy 
m 
 
61 
61 
2007 
2007 
deceased 
deceased 
4 
4 
no M, P, C 
M, P, T 
no 
no 
no 
no 
FD (5a)* 
Diabetic nephropathy 
m 
 
44 
46 
1999 
1999 
deceased (1st) 
living (1st) 
3 
3 
no M, P, C 
M, P, C 
yes 
yes 
yes 
no 
FD (5b)** 
Polycystic kidney disease 
m 
 
56 
57 
2011 
2010 
deceased (2nd) 
deceased (2nd) 
2 
3 
yes 
 
M, P, C 
M, P, T 
no 
no 
yes 
no 
FD (6) 
Malignant nephrosclerosis 
m 
 
44 
42 
2011 
2010 
deceased 
deceased 
4 
5 
no 
 
M, P, C 
M, P, T 
no 
yes 
no 
no 
FD (7) 
Chronic pyelonephritis  
m 
 
17 
18 
1991 
1990 
living  
living 
2 
2 
no A, P, C 
A, P, C 
yes 
yes 
no 
no 
FD (8) 
Chronic pyelonephritis due to VUR 
m 
 
35 
34 
1993 
1993 
deceased 
deceased 
4 
3 
no 
 
P, C 
A, P, C 
no 
yes 
yes 
no 
FD (9) 
Polycystic kidney disease 
m 
 
33 
35 
1979 
1977 
deceased 
deceased 
4 
5 
no A, P 
A, P 
no 
yes 
yes 
no 
FD (10) 
Chronic pyelonephritis due to VUR 
m 
 
28 
28 
1990 
1992 
deceased 
living 
3 
2 
no 
 
A, P, C 
A, P, C 
no 
yes 
yes 
yes 
FD (11) 
Diabetic nephropathy 
m 
 
44 
42 
2014 
2014 
living  
living 
2 
1 
no M, P, T 
M, P, T 
no 
no 
no 
no 
FD (12) 
Chronic pyelonephritis  
m 
 
27 
28 
1998 
1997 
deceased 
living  
3 
3 
no 
 
M, P, C 
M, P, C 
no 
yes 
no 
no 
FD (13) 
Hypertensive nephropathy 
m 
 
53 
52 
2006 
2004 
living 
living 
3 
3 
no 
 
M, P, C 
M, P, C 
no 
no 
no 
no 
FD (14) 
Polycystic kidney disease 
f 
 
56 
57 
2016 
2015 
living  
living 
4 
5 
no M, P, T 
M, P, T 
no 
no 
no 
no 
FD (15) 
Congenital anomalies of the kidney 
m 
 
16 
20 
2013 
2011 
living 
living 
3 
3 
no 
 
M, P, T 
M, P, T 
no 
no 
no 
no 
FD (16) 
Unknown 
f 
 
45 
44 
2015 
2015 
deceased 
deceased 
0 
1 
no 
 
M, P, T 
M, P, T 
no 
no 
no 
no 
FD (17) 
Chronic glomerulonephritis 
m 
 
59 
56 
2002 
2002 
deceased 
deceased 
3 
2 
no 
 
M, P, C 
M, P, C 
no 
yes 
yes 
yes AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
 31 
Table 3a. Demographics, genetic and clinical information and patient outcome in FD recipients.  
Abbreviations: α = agalsidase-α; β = agalsidase-β; α/β or β/α: switch of the ERT; f = female; m = male; mo = months; yrs = years; 5a: 1st transplant; 5b: 2nd transplant. 
 
 
Patient  
& sex 
Phenotype GLA mutation; 
predicted amino 
acid change 
Latest  
age*, yrs 
Year of 
KTx 
Year of 
ERT start 
Type 
of ERT 
Biweekly ERT 
dose (mg/kg) 
Cumulative post-
KTx ERT dose (g) 
Overall sur- 
vival (yrs) 
Deceased 
(+/-) Year 
Cause of 
death  
1 (m) Classic c.125T>C;p.M42T 35 2005 2004 α  0.2 3.4 11.2 -  
2 (m) Classic c.1033T>C; 
p.S345P 
60 1995 2001 α  0.2 5 19.6 2015 Septic  
endocarditis 
3 (m) Classic c.1033T>C;p S345P 
 
61 1993 No - 0 0 15.4 2009 Unknown 
4 (m) Later-Onset c.902G>A; p.R301Q 70 2007 2001 β/α  1.0/0.2 β:6.2/ α:2.2 9.4 -  
5a (m) Classic c.899T>A;p.L300H 59 1999 2004 β  1.0 13 15.2 -  
5b (m)  Classic c.899T>A;p.L300H  2011 2004 β/α  1.0/0.2 β:3.5/ α:0.4 15.2 2014 Cardiac arrest 
6 (m) Classic c.613C>T;p.P205S 49 2011 2004 α  0.2 2.1 5.3   
7 (m) Classic c.370-2A>G;Cons. 
Splice Site 
42 1991 2001 α  0.2 4.4 25.5   
8 (m) Classic c.1167dupT;p.V390Cf
sX9 
 
58 1993 2001 α  0.2 4.8 22.6 2016 Suicide 
9 (m) Classic c.1167dupT; 
p.V390CfsX9 
 
47 1979 No - 0 0 13.8 1993 Cardiac 
arrest, 
Hepatitis B 
10 (m) Classic c.1167dupT; 
p.V390CfsX9 
 
40 1990 No - 0 0 11.6 2002 Brainstem 
compression 
by basilar 
artery 
aneurysm 
11 (m) Classic c.744_745delTA 
;p.F248LfsX7 
 
46 2014 2005 α 0.2 0.9 3 -  
12 (m) Classic c.370-2A>G; Cons. 
Splice Site 
46 1998 2001 α  0.2 4.8 18.8 -  
13 (m) Classic IVS6-10G>A; 
Alternative Splicing 
63 2006 2006 β/α/β  1.0/0.2/1.0 β:16.7/ α:0.3 10.8 -  
14 (f) Later-Onset c.416A>G;p.N139S 57 2016 2013 β  1.0 1.4 0.8 -  
15 (m) Classic c.638A>G;p.K213R  
 
19 2013 2013 α  0.2 1.1 3.6 -  
16 (f) Later-Onset c.109G>A; p.A37T 46 2015 2008 α  0.2 0.5 1.3 -  
17 (m) Classic Not available  69 2002 2001 α  0.2 3.2 10.6 2012 Cardiac arrest AC
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Table 3b. Transplant-related information in the FD recipients. 
Abbreviations: A = Azathioprin, Alb/C = albumin/creatinine, C = Ciclosporine, M = Mycophenolate, P = Prednisone, Pro/C = protein/creatinine, T = Tacrolimus, yrs = 
years. * At the end of follow-up time or latest available results ** The original genetic report of this patient, who died in between, was not any more available. The 
Classic phenotype has been confirmed by clinical symptoms: cardiomyopathy, nephropathy, cornea verticillata, hypohidrosis.  
Patient  Age at 
KTx, yrs 
Year of   
KTx 
Survival of 
KTx, yrs 
Donor type &  
HLA Mismatches 
Immunosuppression 
at baseline   at last 
eGFR 
(ml/min)* 
Serume crea- 
tinine (μmol/l)* 
Pro/C ratio 
(mg/mmol)* 
Alb/C ratio 
(mg/mmol)* 
AT1-/ACE- 
Inhibitors* 
1 24 2005 11.2 living  
(step mother) 
5 M, P, C M, T 60 132 91 53.2 0 
2 40 1995 19.6 deceased 3 A, P, C M, C 56 120 31 n/a 0 
3 45 1993 15.4 deceased 4 A, P, C A, C 56 97 20 n/a 1 
4 61 2007 9.4 deceased 4 M, P, C M, C 18 295 21 11.5 0 
5a 44 1999 9.1 deceased (1st) 3 M, P, C M, C anuric 0 
5b  56 2011 3.2 deceased(2nd) 2 M, P, C M, C 42 154 22 9.3 0 
6 44 2011 5.3 deceased 3 M, P, C M, C 77 99 no 4.3 1 
7 17 1991 21.8 living (father) 2 A, P, C P anuric 1 
8 35 1993 22.6 deceased 4 P, C P, C 43 152 45 18.9 1 
9 33 1979 13.8 deceased 1 A, P A, P n/a n/a n/a n/a n/a 
10 28 1990 11.6 deceased 3 A, P, C A, P, C 27 282 109 n/a 1 
11 44 2014 3 living (father) 3 M, P, T M, T 55 132 7 0.8 1 
12 27 1998 18.8 deceased  2 M, P, C M, C 49 147 9 2.4 0 
13 53 2006 10.8 living (wife) 3 M, P, C M, P, T 63 101 no 0.4 1 
14 56 2016 0.8 living 
(husband) 
4 M, P, T M, P, T 74 77 9.2 0.3 1 
15 16 2013 3.6 living (mother) 3 M, P, T M, T 98 96 9.8 0.8 1 
16 45 2015 1.3 deceased 0 M, P, T M, P, T 49 115 7.8 0.2 0 
17 59 2002 10.6 deceased 3 M, P, C M, C 68 96 29 1.1 1 A
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Table 4. Patient and graft survival at 5, 10, 15, 18 and 20 years. 
Follow-up time Number of patients  Number of grafts  Patient survival Graft survival  
5 years 13 14 100% (13/13) 93% (13/14) 
10 years 11 12 100% (11/11) 92% (11/12) 
15 years 9 10 67% (6/9) 60% (6/10) 
18 years 9 10 44% (4/9) 40% (4/10) 
20 years 8 9 25% (2/8) 22% (2/9) 
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Table 5. FD patients with kidney transplant biopsies.  
 
Patient  Number of 
biopsies 
Kind of microscopy Transplant age at last 
microscopy in months 
No ERT after 
KTx, yrs 
FD-specific changes Other histological changes 
light electron 
1 1 Yes No 0.3 0 No Rejection Banff 1B 
2 3 Yes Yes 4 5.5 No Intima fibrosis, acute interstitial 
nephritis 
3 2 Yes Yes 0.3 15.4 No Intima proliferation 
4 2 Yes Yes 8 0 No Rejection Banff 2A 
5a 2 Yes No 68 4.5 No Interstitial fibrosis, tubular atrophy 
5b 3 Yes Yes 12 0 No Chronic glomerulitis, interstitial 
fibrosis, tubular atrophy 
6 1 Yes No 12 0 No Acute tubular necrosis 
7 2 Yes Yes 262 10 No Rejection Banff 2A, papillary renal 
carcinoma 
8 1 Yes Yes 272 8.4 Single concentric inclusions in 
a migrated host tissue 
macrophage and an 
intercalating histiocyte  
 
Capillaritis with C4d positive 
staining 
9 1* Yes Yes 166 13.8 Abandoned vascular 
endothelial Gb3 deposits, most 
likely migrated from host  
Not reported 
10 1 Yes Yes 140 11.6 No Mild lymphoplasmacellular 
interstitial infiltration and 
arteriolohyalinosis 
15 1 Yes No 0.1 0.25 No Limited focal lymphocytic infiltration 
at cortex/medulla region without 
tubulitis, no vasculitis, no C4d 
staining, no signs of rejection 
 
Abbreviations: ERT = enzyme replacement therapy; FD = Fabry disease; KTx = kidney transplant; yrs = years. * Autopsy  
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Table 6. Case reports of kidney biopsies from the pre-ERT era. 
 
Year of  
Publication 
Authors Timepoint of 
microscopy 
Histological findings 
1972 Clarke et al.20 7 months 
(autopsy) 
EM: intracellular multilamellar bodies, epithelium 
was normal; no accumulation of glycolipids  
1973 Bühler et al.12 17 months  
(autopsy) 
No deposits 
1981 Faraggiana et al.21 6 months LM: glomerular, tubular and interstitial deposits  
EM: few inclusions on the vascular endothelium 
1982 Clement et al.57 15 months  
(autopsy) 
LM and EM: normal 
1982 Bannwart et al.58 12 yrs LM and EM: normal 
1986 McMahon et al.23  4 yrs Accumulation in endothelial cells leading to 
narrowing and occlusions 
1987 Friedlaender et al.22 8 yrs LM: no abnormalities 
EM: occasional small myelin figures in the 
vascular endothelium 
1987 Popli et al.54 5.5 yrs donor was heterozygous sister 
LM and EM: FD typical changes 
1991 Mosnier et al.59 11 yrs  
(autopsy) 
LM: normal 
EM: sphingolipid inclusions in the vascular 
endothelium 
1995 Gantenbein et al.28 14 yrs 
(autopsy) 
LM: no abnormalities 
EM: massive tubular, interstitial and endothelial 
deposits of Gb3 
1998 Erten et al.60 10 yrs LM and EM: normal 
Abbreviations: EM= electron microscopy; FD= Fabry Disease; LM = light microscopy; yrs, years AC
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